Cristina Gasparetto | Scholars@Duke

Cristina Gasparetto
Professor of Medicine

Dr. Gasparetto performs both laboratory and clinical research in the field of multiple myeloma. Her primary research interests are in developing immunotherapy approaches to treating multiple myeloma particularly in conjunction with hematopoietic stem cell transplantation. Ongoing laboratory research projects include the development of dendritic cell vaccines and antibody therapies. Clinical studies include a recently approved trial involving vaccination with autologous dendritic cells pulsed with idiotypic protein following high dose chemotherapy and autologous peripheral blood stem cells transplant. Upcoming trials include novel antibody therapies for multiple myeloma. Dr. Gasparetto is also an investigator on several other clinical trials for myeloma including non-myeloablative allogeneic transplantation, high dose sequential chemotherapy and autologous peripheral blood stem cell transplantation and transplantation of partially HLA matched unrelated cord blood.

Current Appointments & Affiliations

Professor of Medicine, Medicine, Hematologic Malignancies and Cellular Therapy, Medicine 2018
Member of the Duke Cancer Institute, Duke Cancer Institute, Institutes and Centers 1993

Contact Information

9058 North Pavilion, Durham, NC 27710
Box 3961 Med Ctr, Durham, NC 27710
gaspa001@mc.duke.edu (919) 668-1017

Background
Education, Training, & Certifications
- Fellow in Hematology/Oncology, Medicine, Duke University 1996 - 1999
- Medical Resident, Medicine, Duke University 1993 - 1996
- M.D., Sapienza University of Rome (Italy) 1986
Duke Appointment History
- Associate Professor of Medicine, Medicine, Hematologic Malignancies and Cellular Therapy, Medicine 2012 - 2018
- Associate Professor of Medicine, Medicine, Hematologic Malignancies and Cellular Therapy, Medicine 2008 - 2012
- Assistant Professor of Medicine, Medicine, Hematologic Malignancies and Cellular Therapy, Medicine 2002 - 2008
- Associate in the Department of Medicine, Medicine, Medical Oncology, Medicine 1999 - 2002
- Instructor, Temporary in the Department of Medicine, Medicine, Medical Oncology, Medicine 1999
Research
Selected Grants
- Venetoclax ABT-199 awarded by AbbVie Inc. 2018 - 2023
- M15 654 awarded by AbbVie Inc. 2018 - 2023
- NP39403 awarded by F. Hoffmann-La Roche Ltd 2018 - 2023
- A Phase 1, Open Label Study to evaluate the safety Pharmacokinetic, Pharmacodynamic and clinical activity of PF-06863135, A B-Cell Maturation Antigen (BCMA)- CD3 Bispecifi Antibody In Patient awarded by Pfizer, Inc. 2018 - 2023
- AbbVie M15 538 awarded by AbbVie Inc. 2018 - 2023
- Protocol 54767414MMY2004 Phase 2 awarded by Janssen Research & Development, LLC 2017 - 2022
- Study to evaluate the safety of SAR650984 (isatuximab) in R/R MM pts awarded by Sanofi US 2017 - 2021
- Phase III double blind study of Bortezomib and Dex in combination with Venetoclax or Placebo in R/R MM awarded by AbbVie Inc. 2016 - 2021
- A Feasibility Phase II study of BEAM followed by MLN 9708 Maintenance therapy in high risk MM patients awarded by Oregon Health & Science University 2016 - 2021
- Ph 3 Trial of Combinations of Nivolumab, Elotuzumab, Pomalidomide and Dexamethasone awarded by Bristol-Myers Squibb Company 2016 - 2021
- Phase Ib/2 Study of Selinexor (KPT330) for R/R MM awarded by Karyopharm Therapeutics 2016 - 2021
- Transfusion Medicine and Hematology awarded by National Institutes of Health 1975 - 2021
- Phase 1/2 Open label study of SL-401 with Pom/Dex in R/R MM awarded by Stemline Therapeutics, Inc 2016 - 2021
- Phase III study of Pomalidomide and low dose Dex with or without Pembrolizumab (MK3475) in MM awarded by Merck Sharp & Dohme 2016 - 2021
- A Phase I Study of ABT-199 Monotherapy in R/R Multiple Myeloma awarded by AbbVie Inc. 2015 - 2020
- Phase 1/2b study of Ibrutinib with Carlfizomib with R/R Myeloma awarded by Pharmacyclics, Inc. 2013 - 2019
- An Observational Study on Newly Diagnosed MM to assess the realtionship between patient outcomes, treatment regimens awarded by Multiple Myeloma Research Foundation 2013 - 2018
- NEOD001 awarded by Prothena Therapeutics Limited 2017 - 2018
- A Phase II study of Filanesib (ARRY-520) with patients with Advanced Multiple Myeloma awarded by Array BioPharma Inc 2014 - 2018
- CELGENE MULTIPLE MYELOMA TUMOR PRACTICUM awarded by Celgene Corporation 2017
- Randomized Phase II trial study of lenalidomide, bortezomib and dexamethsone (RVD) in new MM pts awarded by Novartis Pharmaceuticals Corporation 2016 - 2017
- Phase II, study of Selinexor KPT-330 Carlf, and Dexa, in R/R MM pts awarded by Karyopharm Therapeutics 2016 - 2017
- KPT-330 (KCP-330-011) SLAM in R/R MM awarded by Karyopharm Therapeutics 2015 - 2017
- Dendritic Cell Based Vaccination for Multiple Myeloma awarded by National Institutes of Health 2002 - 2007
Publications & Artistic Works
Selected Publications
- Academic Articles
  - Zheng, J, Sha, Y, Roof, L, Foreman, O, Lazarchick, J, Venkta, JK, Kozlowski, C, Gasparetto, C, Chao, N, Ebens, A, Hu, J, and Kang, Y. "Pan-PIM kinase inhibitors enhance Lenalidomide's anti-myeloma activity via cereblon-IKZF1/3 cascade.(Accepted)" Cancer Letters 440-441 (January 2019): 1-10. Full Text
  - Abonour, R, Wagner, L, Durie, BGM, Jagannath, S, Narang, M, Terebelo, HR, Gasparetto, CJ, Toomey, K, Hardin, JW, Kitali, A, Gibson, CJ, Srinivasan, S, Swern, AS, and Rifkin, RM. "Impact of post-transplantation maintenance therapy on health-related quality of life in patients with multiple myeloma: data from the Connect® MM Registry." Annals of Hematology 97, no. 12 (December 2018): 2425-2436. Full Text
  - Sivaraj, D, Green, MM, Kang, Y, Long, GD, Rizzieri, DA, Li, Z, Garrett, AH, McIntyre, JL, Chao, NJ, and Gasparetto, C. "Bendamustine, pomalidomide, and dexamethasone for relapsed and/or refractory multiple myeloma." Blood Cancer Journal 8, no. 8 (July 31, 2018): 71-null. Full Text
  - Rifkin, RM, Jagannath, S, Durie, BGM, Narang, M, Terebelo, HR, Gasparetto, CJ, Toomey, K, Hardin, JW, Wagner, L, Parikh, K, Abouzaid, S, Srinivasan, S, Kitali, A, Zafar, F, and Abonour, R. "Treatment Outcomes and Health Care Resource Utilization in Patients With Newly Diagnosed Multiple Myeloma Receiving Lenalidomide-only Maintenance, Any Maintenance, or No Maintenance: Results from the Connect MM Registry." Clinical Therapeutics 40, no. 7 (July 23, 2018): 1193-1202.e1. (Review) Full Text
  - Jagannath, S, Abonour, R, Durie, BGM, Gasparetto, C, Hardin, JW, Narang, M, Terebelo, HR, Toomey, K, Wagner, L, Srinivasan, S, Kitali, A, Yue, L, Flick, ED, Agarwal, A, and Rifkin, RM. "Heterogeneity of Second-Line Treatment for Patients With Multiple Myeloma in the Connect MM Registry (2010-2016)." Clinical Lymphoma, Myeloma & Leukemia 18, no. 7 (July 2018): 480-485.e3. Full Text
  - Sundaramoorthy, P, Gasparetto, C, and Kang, Y. "The combination of a sphingosine kinase 2 inhibitor (ABC294640) and a Bcl-2 inhibitor (ABT-199) displays synergistic anti-myeloma effects in myeloma cells without a t(11;14) translocation." Cancer Medicine (May 15, 2018). Full Text
  - Kumar, SK, Dispenzieri, A, Fraser, R, Mingwei, F, Akpek, G, Cornell, R, Kharfan-Dabaja, M, Freytes, C, Hashmi, S, Hildebrandt, G, Holmberg, L, Kyle, R, Lazarus, H, Lee, C, Mikhael, J, Nishihori, T, Tay, J, Usmani, S, Vesole, D, Vij, R, Wirk, B, Krishnan, A, Gasparetto, C, Mark, T, Nieto, Y, Hari, P, and D'Souza, A. "Early relapse after autologous hematopoietic cell transplantation remains a poor prognostic factor in multiple myeloma but outcomes have improved over time." Leukemia 32, no. 4 (April 2018): 986-995. Full Text
  - Htut, M, D'Souza, A, Krishnan, A, Bruno, B, Zhang, M-J, Fei, M, Diaz, MA, Copelan, E, Ganguly, S, Hamadani, M, Kharfan-Dabaja, M, Lazarus, H, Lee, C, Meehan, K, Nishihori, T, Saad, A, Seo, S, Ramanathan, M, Usmani, SZ, Gasparetto, C, Mark, TM, Nieto, Y, and Hari, P. "Autologous/Allogeneic Hematopoietic Cell Transplantation versus Tandem Autologous Transplantation for Multiple Myeloma: Comparison of Long-Term Postrelapse Survival." Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 24, no. 3 (March 2018): 478-485. Full Text
  - Zheng, Z, Fan, S, Zheng, J, Huang, W, Gasparetto, C, Chao, NJ, Hu, J, and Kang, Y. "Inhibition of thioredoxin activates mitophagy and overcomes adaptive bortezomib resistance in multiple myeloma." Journal of hematology & oncology 11, no. 1 (February 27, 2018): 29-. Full Text
  - Sivaraj, D, Bacon, W, Long, GD, Rizzieri, DA, Horwitz, ME, Sullivan, KM, Kang, Y, Li, Z, Chao, NJ, and Gasparetto, C. "High-dose BCNU/Melphalan conditioning regimen before autologous stem cell transplantation in newly diagnosed multiple myeloma." Bone marrow transplantation 53, no. 1 (January 2018): 34-38. Full Text
  - Huang, L-W, Bacon, W, Cirrincione, C, Peterson, B, Long, G, Rizzieri, D, Sullivan, KM, Corbet, K, Horwitz, M, Chao, N, Gasparetto, C, and Tuchman, SA. "Efficacy and safety of high-dose chemotherapy with autologous stem cell transplantation in senior versus younger adults with newly diagnosed multiple myeloma." Hematological oncology 35, no. 4 (December 2017): 752-759. Full Text
  - Shah, JJ, Abonour, R, Gasparetto, C, Hardin, JW, Toomey, K, Narang, M, Srinivasan, S, Kitali, A, Zafar, F, Flick, ED, and Rifkin, RM. "Analysis of Common Eligibility Criteria of Randomized Controlled Trials in Newly Diagnosed Multiple Myeloma Patients and Extrapolating Outcomes." Clinical Lymphoma, Myeloma & Leukemia 17, no. 9 (September 2017): 575-583.e2. Full Text
  - Terebelo, H, Srinivasan, S, Narang, M, Abonour, R, Gasparetto, C, Toomey, K, Hardin, JW, Larkins, G, Kitali, A, Rifkin, RM, and Shah, JJ. "Recognition of early mortality in multiple myeloma by a prediction matrix." American Journal of Hematology 92, no. 9 (September 2017): 915-923. Full Text
  - Vogl, DT, Martin, TG, Vij, R, Hari, P, Mikhael, JR, Siegel, D, Wu, KL, Delforge, M, and Gasparetto, C. "Phase I/II study of the novel proteasome inhibitor delanzomib (CEP-18770) for relapsed and refractory multiple myeloma." Leukemia & lymphoma 58, no. 8 (August 2017): 1872-1879. Full Text
  - Anand, S, Thomas, S, Hyslop, T, Adcock, J, Corbet, K, Gasparetto, C, Lopez, R, Long, GD, Morris, AK, Rizzieri, DA, Sullivan, KM, Sung, AD, Sarantopoulos, S, Chao, NJ, and Horwitz, ME. "Transplantation of Ex Vivo Expanded Umbilical Cord Blood (NiCord) Decreases Early Infection and Hospitalization." Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation 23, no. 7 (July 2017): 1151-1157. Full Text
  - Voorhees, PM, Gasparetto, C, Moore, DT, Winans, D, Orlowski, RZ, and Hurd, DD. "Final Results of a Phase 1 Study of Vorinostat, Pegylated Liposomal Doxorubicin, and Bortezomib in Relapsed or Refractory Multiple Myeloma." Clinical Lymphoma, Myeloma & Leukemia 17, no. 7 (July 2017): 424-432. Full Text
  - Sivaraj, D, Green, MM, and Gasparetto, C. "Panobinostat for the management of multiple myeloma." Future Oncology (London, England) 13, no. 6 (March 2017): 477-488. (Review) Full Text
  - Kumar, SK, Callander, NS, Alsina, M, Atanackovic, D, Biermann, JS, Chandler, JC, Costello, C, Faiman, M, Fung, HC, Gasparetto, C, Godby, K, Hofmeister, C, Holmberg, L, Holstein, S, Huff, CA, Kassim, A, Liedtke, M, Martin, T, Omel, J, Raje, N, Reu, FJ, Singhal, S, Somlo, G, Stockerl-Goldstein, K, Treon, SP, Weber, D, Yahalom, J, Shead, DA, and Kumar, R. "Clinical practice guidelines in oncology." Jnccn Journal of the National Comprehensive Cancer Network 15, no. 2 (February 1, 2017): 230-269.
  - Sivaraj, D, Green, MM, Li, Z, Sung, AD, Sarantopoulos, S, Kang, Y, Long, GD, Horwitz, ME, Lopez, RD, Sullivan, KM, Rizzieri, DA, Chao, NJ, and Gasparetto, C. "Outcomes of Maintenance Therapy with Bortezomib after Autologous Stem Cell Transplantation for Patients with Multiple Myeloma." Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation 23, no. 2 (February 2017): 262-268. Full Text
  - LeBlanc, TW, Howson, A, Turell, W, Sheldon, P, Locke, SC, Tuchman, SA, Gasparetto, C, Kaura, S, Khan, ZM, and Abernethy, AP. "Risk stratification, treatment selection, and transplant eligibility in multiple myeloma: a qualitative study of the perspectives and self-reported practices of oncologists." Current Oncology (Toronto, Ont.) 23, no. 6 (December 21, 2016): e598-e604. Full Text
  - Scott, EC, Hari, P, Sharma, M, Le-Rademacher, J, Huang, J, Vogl, D, Abidi, M, Beitinjaneh, A, Fung, H, Ganguly, S, Hildebrandt, G, Holmberg, L, Kalaycio, M, Kumar, S, Kyle, R, Lazarus, H, Lee, C, Maziarz, RT, Meehan, K, Mikhael, J, Nishihori, T, Ramanathan, M, Usmani, S, Tay, J, Vesole, D, Wirk, B, Yared, J, Savani, BN, Gasparetto, C, Krishnan, A, Mark, T, Nieto, Y, and D'Souza, A. "Post-Transplant Outcomes in High-Risk Compared with Non-High-Risk Multiple Myeloma: A CIBMTR Analysis." Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 22, no. 10 (October 2016): 1893-1899. Full Text
  - Sung, AD, Sung, JAM, Thomas, S, Hyslop, T, Gasparetto, C, Long, G, Rizzieri, D, Sullivan, KM, Corbet, K, Broadwater, G, Chao, NJ, and Horwitz, ME. "Universal Mask Usage for Reduction of Respiratory Viral Infections After Stem Cell Transplant: A Prospective Trial." Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America 63, no. 8 (October 2016): 999-1006. Full Text
  - Rifkin, RM, Abonour, R, Shah, JJ, Mehta, J, Narang, M, Terebelo, H, Gasparetto, C, Toomey, K, Hardin, JW, Lu, JJ, Kenvin, L, Srinivasan, S, Knight, R, Nagarwala, Y, and Durie, BGM. "Connect MM® - the Multiple Myeloma Disease Registry: incidence of second primary malignancies in patients treated with lenalidomide." Leukemia & Lymphoma 57, no. 9 (September 2016): 2228-2231. (Letter) Full Text
  - Green, MMB, Chao, N, Chhabra, S, Corbet, K, Gasparetto, C, Horwitz, A, Li, Z, Venkata, JK, Long, G, Mims, A, Rizzieri, D, Sarantopoulos, S, Stuart, R, Sung, AD, Sullivan, KM, Costa, L, Horwitz, M, and Kang, Y. "Plerixafor (a CXCR4 antagonist) following myeloablative allogeneic hematopoietic stem cell transplantation enhances hematopoietic recovery." Journal of Hematology & Oncology 9, no. 1 (August 17, 2016): 71-null. Full Text Open Access Copy
  - Sivaraj, D, Green, MM, Ciftci, AM, Zahid, MF, Johns, AA, Ross, M, and Gasparetto, C. "Can We Cure Light Chain Deposition Disease of the Kidneys?-A Review and Case Report of a Patient Treated With a Triple Transplant Approach." Clinical lymphoma, myeloma & leukemia 16, no. 6 (June 2016): e95-e100. (Review) Full Text
  - Anderson, KC, Alsina, M, Atanackovic, D, Biermann, JS, Chandler, JC, Costello, C, Djulbegovic, B, Fung, HC, Gasparetto, C, Godby, K, Hofmeister, C, Holmberg, L, Holstein, S, Huff, CA, Kassim, A, Krishnan, AY, Kumar, SK, Liedtke, M, Lunning, M, Raje, N, Reu, FJ, Singhal, S, Somlo, G, Stockerl-Goldstein, K, Treon, SP, Weber, D, Yahalom, J, Shead, DA, and Kumar, R. "NCCN guidelines^® insights multiple myeloma, version 3.2016 featured updates to the NCCN guidelines." Jnccn Journal of the National Comprehensive Cancer Network 14, no. 4 (April 1, 2016): 389-400. Full Text
  - Shah, JJ, Stadtmauer, EA, Abonour, R, Cohen, AD, Bensinger, WI, Gasparetto, C, Kaufman, JL, Lentzsch, S, Vogl, DT, Gomes, CL, Pascucci, N, Smith, DD, Orlowski, RZ, and Durie, BGM. "Carfilzomib, pomalidomide, and dexamethasone for relapsed or refractory myeloma." Blood 126, no. 20 (November 2015): 2284-2290. Full Text
  - Rifkin, RM, Abonour, R, Terebelo, H, Shah, JJ, Gasparetto, C, Hardin, J, Srinivasan, S, Ricafort, R, Nagarwala, Y, and Durie, BGM. "Connect MM Registry: The Importance of Establishing Baseline Disease Characteristics." Clinical Lymphoma, Myeloma & Leukemia 15, no. 6 (June 2015): 368-376. Full Text
  - Tuchman, SA, Bacon, WA, Huang, L-W, Long, G, Rizzieri, D, Horwitz, M, Chute, JP, Sullivan, K, Morris Engemann, A, Yopp, A, Li, Z, Corbet, K, Chao, N, and Gasparetto, C. "Cyclophosphamide-based hematopoietic stem cell mobilization before autologous stem cell transplantation in newly diagnosed multiple myeloma." Journal of Clinical Apheresis 30, no. 3 (June 2015): 176-182. Full Text
  - Tuchman, SA, Lane, A, Hornsby, WE, Bishop, C, Thomas, S, Herndon, JE, Long, G, Gasparetto, C, and Jones, LW. "Quantitative measures of physical functioning after autologous hematopoietic stem cell transplantation in multiple myeloma: a feasibility study." Clinical lymphoma, myeloma & leukemia 15, no. 2 (February 2015): 103-109. Full Text
  - Rifkin, RM, Abonour, R, Terebelo, H, Shah, JJ, Gasparetto, C, Hardin, J, Srinivasan, S, Ricafort, R, Nagarwala, Y, and Durie, BGM. "Connect MM registry: The importance of establishing baseline disease characteristics." Clinical Lymphoma, Myeloma and Leukemia 15, no. 6 (January 1, 2015): 368-376. Full Text
  - Tuchman, SA, Bacon, WA, Huang, LW, Long, G, Rizzieri, D, Horwitz, M, Chute, JP, Sullivan, K, Engemann, AM, Yopp, A, Li, Z, Corbet, K, Chao, N, and Gasparetto, C. "Cyclophosphamide-based hematopoietic stem cell mobilization before autologous stem cell transplantation in newly diagnosed multiple myeloma." Journal of Clinical Apheresis 30, no. 3 (January 1, 2015): 176-182. Full Text
  - Sharma, M, Zhang, M-J, Zhong, X, Abidi, MH, Akpek, G, Bacher, U, Callander, NS, Dispenzieri, A, Freytes, CO, Fung, HC, Gale, RP, Gasparetto, C, Gibson, J, Holmberg, LA, Kindwall-Keller, TL, Klumpp, TR, Krishnan, AY, Landau, HJ, Lazarus, HM, Lonial, S, Maiolino, A, Marks, DI, Mehta, P, Mikhael Med, JR, Nishihori, T, Olsson, R, Ramanathan, M, Roy, V, Savani, BN, Schouten, HC, Scott, E, Tay, J, To, LB, Vesole, DH, Vogl, DT, and Hari, P. "Older patients with myeloma derive similar benefit from autologous transplantation." Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation 20, no. 11 (November 2014): 1796-1803. Full Text
  - Horwitz, ME, Chao, NJ, Rizzieri, DA, Long, GD, Sullivan, KM, Gasparetto, C, Chute, JP, Morris, A, McDonald, C, Waters-Pick, B, Stiff, P, Wease, S, Peled, A, Snyder, D, Cohen, EG, Shoham, H, Landau, E, Friend, E, Peleg, I, Aschengrau, D, Yackoubov, D, Kurtzberg, J, and Peled, T. "Umbilical cord blood expansion with nicotinamide provides long-term multilineage engraftment." The Journal of Clinical Investigation 124, no. 7 (July 2014): 3121-3128. Full Text
  - Saad, A, Mahindra, A, Zhang, M-J, Zhong, X, Costa, LJ, Dispenzieri, A, Drobyski, WR, Freytes, CO, Gale, RP, Gasparetto, CJ, Holmberg, LA, Kamble, RT, Krishnan, AY, Kyle, RA, Marks, D, Nishihori, T, Pasquini, MC, Ramanathan, M, Lonial, S, Savani, BN, Saber, W, Sharma, M, Sorror, ML, Wirk, BM, and Hari, PN. "Hematopoietic Cell Transplant Comorbidity Index Is Predictive of Survival after Autologous Hematopoietic Cell Transplantation in Multiple Myeloma." Biology of Blood and Marrow Transplantation 20, no. 3 (March 2014): 402-408.e1. Full Text
  - Saad, A, Mahindra, A, Zhang, M-J, Zhong, X, Costa, LJ, Dispenzieri, A, Drobyski, WR, Freytes, CO, Gale, RP, Gasparetto, CJ, Holmberg, LA, Kamble, RT, Krishnan, AY, Kyle, RA, Marks, D, Nishihori, T, Pasquini, MC, Ramanathan, M, Lonial, S, Savani, BN, Saber, W, Sharma, M, Sorror, ML, Wirk, BM, and Hari, PN. "Hematopoietic cell transplant comorbidity index is predictive of survival after autologous hematopoietic cell transplantation in multiple myeloma." Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation 20, no. 3 (March 2014): 402-408.e1. Full Text
  - Kanda, J, Long, GD, Gasparetto, C, Horwitz, ME, Sullivan, KM, Chute, JP, Morris, A, Shafique, M, Li, Z, Chao, NJ, and Rizzieri, DA. "Reduced-intensity allogeneic transplantation using alemtuzumab from HLA-matched related, unrelated, or haploidentical related donors for patients with hematologic malignancies." Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation 20, no. 2 (February 2014): 257-263. Full Text
  - Sharma, M, Zhang, MJ, Zhong, X, Abidi, MH, Akpek, G, Bacher, U, Callander, NS, Dispenzieri, A, Freytes, CO, Fung, HC, Gale, RP, Gasparetto, C, Gibson, J, Holmberg, LA, Kindwall-Keller, TL, Klumpp, TR, Krishnan, AY, Landau, HJ, Lazarus, HM, Lonial, S, Maiolino, A, Marks, DI, Mehta, P, Mikhael Med, JR, Nishihori, T, Olsson, R, Ramanathan, M, Roy, V, Savani, BN, Schouten, HC, Scott, E, Tay, J, To, LB, Vesole, DH, Vogl, DT, and Hari, P. "Older Patients with Myeloma Derive Similar Benefit from Autologous Transplantation." Biology of Blood and Marrow Transplantation 20, no. 11 (January 1, 2014): 1796-1803. Full Text
  - Kanda, J, Kaynar, L, Kanda, Y, Prasad, VK, Parikh, SH, Lan, L, Shen, T, Rizzieri, DA, Long, GD, Sullivan, KM, Gasparetto, C, Chute, JP, Morris, A, Winkel, S, McPherson, J, Kurtzberg, J, Chao, NJ, and Horwitz, ME. "Pre-engraftment syndrome after myeloablative dual umbilical cord blood transplantation: risk factors and response to treatment." Bone Marrow Transplant 48, no. 7 (July 2013): 926-931. Full Text Link to Item
  - Held, LA, Rizzieri, D, Long, GD, Gockerman, JP, Diehl, LF, de Castro, CM, Moore, JO, Horwitz, ME, Chao, NJ, and Gasparetto, C. "A Phase I study of arsenic trioxide (Trisenox), ascorbic acid, and bortezomib (Velcade) combination therapy in patients with relapsed/refractory multiple myeloma." Cancer Investigation 31, no. 3 (March 2013): 172-176. Full Text
  - Anderson, KC, Alsina, M, Bensinger, W, Biermann, JS, Cohen, AD, Devine, S, Djulbegovic, B, Faber, EA, Gasparetto, C, Hernandez-Illizaliturri, F, Huff, CA, Kassim, A, Krishnan, AY, Liedtke, M, Meredith, R, Raje, N, Schriber, J, Singhal, S, Somlo, G, Stockerl-Goldstein, K, Treon, SP, Weber, D, Yahalom, J, Yunus, F, Shead, DA, and Kumar, R. "Multiple myeloma, version 1.2013." Journal of the National Comprehensive Cancer Network : Jnccn 11, no. 1 (January 2013): 11-17. Full Text
  - Kanda, J, Kaynar, L, Kanda, Y, Prasad, VK, Parikh, SH, Lan, L, Shen, T, Rizzieri, DA, Long, GD, Sullivan, KM, Gasparetto, C, Chute, JP, Morris, A, Winkel, S, McPherson, J, Kurtzberg, J, Chao, NJ, and Horwitz, ME. "Pre-engraftment syndrome after myeloablative dual umbilical cord blood transplantation: Risk factors and response to treatment." Bone Marrow Transplantation 48, no. 7 (2013): 926-931. Full Text
  - Kanda, J, Chiou, L-W, Szabolcs, P, Sempowski, GD, Rizzieri, DA, Long, GD, Sullivan, KM, Gasparetto, C, Chute, JP, Morris, A, McPherson, J, Hale, J, Livingston, JA, Broadwater, G, Niedzwiecki, D, Chao, NJ, and Horwitz, ME. "Immune recovery in adult patients after myeloablative dual umbilical cord blood, matched sibling, and matched unrelated donor hematopoietic cell transplantation." Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation 18, no. 11 (November 2012): 1664-1676.e1. Full Text
  - Spasojevic, I, da Costa, LRS, Horwitz, ME, Long, GD, Sullivan, KM, Chute, JP, Gasparetto, C, Morris, A, Chao, NJ, and Rizzieri, DA. "Mini test dose of intravenous busulfan (busulfex(®)) in allogeneic non-myeloablative stem cell transplantation, followed by liquid chromatography tandem-mass spectrometry." Cancer Investigation 30, no. 9 (November 2012): 679-682. Full Text
  - Anderson, KC, Alsina, M, Bensinger, W, Biermann, JS, Cohen, AD, Devine, S, Djulbegovic, B, Jr, FEA, Gasparetto, C, Hernandez-Ilizaliturri, F, Huff, CA, Kassim, A, Krishnan, AY, Medeiros, BC, Meredith, R, Raje, N, Schriber, J, Singhal, S, Somlo, G, Stockerl-Goldstein, K, Treon, SP, Tricot, G, Weber, DM, Yahalom, J, Yunus, F, Kumar, R, and Shead, DA. "Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma, Version 2.2013 Featured Updates to the NCCN Guidelines." JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK 10, no. 10 (October 2012): 1211-1219. Full Text Link to Item
  - Horwitz, ME, Chute, JP, Gasparetto, C, Long, GD, McDonald, C, Morris, A, Rizzieri, DA, Sullivan, KM, and Chao, NJ. "Preemptive dosing of plerixafor given to poor stem cell mobilizers on day 5 of G-CSF administration." Bone Marrow Transplant 47, no. 8 (August 2012): 1051-1055. Full Text Link to Item
  - Chen, D-F, Prasad, VK, Broadwater, G, Reinsmoen, NL, DeOliveira, A, Clark, A, Sullivan, KM, Chute, JP, Horwitz, ME, Gasparetto, C, Long, GD, Yang, Y, Chao, NJ, and Rizzieri, DA. "Differential impact of inhibitory and activating Killer Ig-Like Receptors (KIR) on high-risk patients with myeloid and lymphoid malignancies undergoing reduced intensity transplantation from haploidentical related donors." Bone Marrow Transplant 47, no. 6 (June 2012): 817-823. Full Text Link to Item
  - Kanda, J, Horwitz, ME, Long, GD, Gasparetto, C, Sullivan, KM, Chute, JP, Morris, A, Hennig, T, Li, Z, Chao, NJ, and Rizzieri, DA. "Outcomes of a 1-day nonmyeloablative salvage regimen for patients with primary graft failure after allogeneic hematopoietic cell transplantation." Bone Marrow Transplant 47, no. 5 (May 2012): 700-705. Full Text Link to Item
  - Tuchman, SA, Chao, NJ, and Gasparetto, CG. "Lenalidomide before and after Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma." Adv Hematol 2012 (2012): 712613-. Full Text Link to Item
  - Kanda, J, Rizzieri, DA, Gasparetto, C, Long, GD, Chute, JP, Sullivan, KM, Morris, A, Smith, CA, Hogge, DE, Nitta, J, Song, K, Niedzwiecki, D, Chao, NJ, and Horwitz, ME. "Adult dual umbilical cord blood transplantation using myeloablative total body irradiation (1350 cGy) and fludarabine conditioning." Biol Blood Marrow Transplant 17, no. 6 (June 2011): 867-874. Full Text Link to Item
  - Craciunescu, OI, Steffey, BA, Kelsey, CR, Larrier, NA, Paarz-Largay, CJ, Prosnitz, RG, Chao, N, Chute, J, Gasparetto, C, Horwitz, M, Long, G, Rizzieri, D, and Sullivan, KM. "Renal shielding and dosimetry for patients with severe systemic sclerosis receiving immunoablation with total body irradiation in the scleroderma: cyclophosphamide or transplantation trial." International Journal of Radiation Oncology, Biology, Physics 79, no. 4 (March 2011): 1248-1255. Full Text
  - Anderson, KC, Alsina, M, Bensinger, W, Biermanft, JS, Chanan-Khan, A, Cohen, AL, Devine, S, Djulbegovic, B, Jr, EAF, Gasparetto, C, Huff, CA, Kassim, A, Medeiros, BC, Meredith, R, Raje, N, Schriber, J, Singhal, S, Somlo, G, Stockerl-Goldstein, K, Treon, SP, Tricof, G, Weber, DM, Yahalom, JH, and Yunus, F. "Multiple myeloma clinical practice guidelines in oncology." JNCCN Journal of the National Comprehensive Cancer Network 9, no. 10 (2011): 1146-1183.
  - Lokhorst, H, Einsele, H, Vesole, D, Bruno, B, Miguel, JS, Perez-Simon, JA, Kröger, NM, Moreau, P, Gahrton, GCA, Gasparetto, C, Giralt, S, and Bensinger, WI. "Reply to A. Gratwohl." Journal of Clinical Oncology 29, no. 16 (2011): e484-. Full Text
  - Rizzieri, DA, Crout, C, Storms, R, Golob, J, Long, GD, Gasparetto, C, Sullivan, KM, Horwitz, M, Chute, J, Lagoo, AS, Morris, A, Beaven, A, Yang, Y, Peterson, B, Li, Z, and Chao, NJ. "Feasibility of low-dose interleukin-2 therapy following T-cell-depleted nonmyeloablative allogeneic hematopoietic stem cell transplantation from HLA-matched or -mismatched family member donors." Cancer Invest 29, no. 1 (January 2011): 56-61. Full Text Link to Item
  - Lokhorst, H, Einsele, H, Vesole, D, Bruno, B, San Miguel, J, Pérez-Simon, JA, Kröger, N, Moreau, P, Gahrton, G, Gasparetto, C, Giralt, S, Bensinger, W, and International Myeloma Working Group, . "International Myeloma Working Group consensus statement regarding the current status of allogeneic stem-cell transplantation for multiple myeloma." Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology 28, no. 29 (October 2010): 4521-4530. Full Text
  - Rizzieri, DA, Storms, R, Chen, D-F, Long, G, Yang, Y, Nikcevich, DA, Gasparetto, C, Horwitz, M, Chute, J, Sullivan, K, Hennig, T, Misra, D, Apple, C, Baker, M, Morris, A, Green, PG, Hasselblad, V, and Chao, NJ. "Natural killer cell-enriched donor lymphocyte infusions from A 3-6/6 HLA matched family member following nonmyeloablative allogeneic stem cell transplantation." Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation 16, no. 8 (August 2010): 1107-1114. Full Text
  - Crout, CA, Koh, L-P, Gockerman, JP, Moore, JO, Decastro, C, Long, GD, Diehl, L, Gasparetto, C, Niedzwiecki, D, Edwards, J, Prosnitz, L, Horwitz, M, Chute, J, Morris, A, Davis, P, Beaven, A, Chao, NJ, Ali-Osman, F, and Rizzieri, DA. "Overcoming drug resistance in mantle cell lymphoma using a combination of dose-dense and intense therapy." Cancer Invest 28, no. 6 (July 2010): 654-660. Full Text Link to Item
  - Kumar, SK, Flinn, I, Noga, SJ, Hari, P, Rifkin, R, Callander, N, Bhandari, M, Wolf, JL, Gasparetto, C, Krishnan, A, Grosman, D, Glass, J, Sahovic, EA, Shi, H, Webb, IJ, Richardson, PG, and Rajkumar, SV. "Bortezomib, dexamethasone, cyclophosphamide and lenalidomide combination for newly diagnosed multiple myeloma: phase 1 results from the multicenter EVOLUTION study." Leukemia 24, no. 7 (July 2010): 1350-1356. Full Text Link to Item
  - Gasparetto, C, Gockerman, JP, Diehl, LF, de Castro, CM, Moore, JO, Long, GD, Horwitz, ME, Keogh, G, Chute, JP, Sullivan, KM, Neuwirth, R, Davis, PH, Sutton, LM, Anderson, RD, Chao, NJ, and Rizzieri, D. ""Short course" bortezomib plus melphalan and prednisone as induction prior to transplant or as frontline therapy for nontransplant candidates in patients with previously untreated multiple myeloma." Biol Blood Marrow Transplant 16, no. 1 (January 2010): 70-77. Full Text Link to Item
  - Anderson, KC, Alsina, M, Bensinger, W, Biermann, JS, Chanan-Khan, A, Cohen, AD, Devine, S, Djulbegovic, B, Gasparetto, C, Huff, CA, Jagasia, M, Medeiros, BC, Meredith, R, Raje, N, Schriber, J, Singhal, S, Somlo, G, Stockerl-Goldstein, K, Tricot, G, Vose, JM, Weber, D, Yahalom, J, Yunus, F, and National Comprehensive Cancer Network, . "NCCN clinical practice guidelines in oncology: multiple myeloma." Journal of the National Comprehensive Cancer Network : Jnccn 7, no. 9 (October 2009): 908-942. Full Text
  - Anguiano, A, Tuchman, SA, Acharya, C, Salter, K, Gasparetto, C, Zhan, F, Dhodapkar, M, Nevins, J, Barlogie, B, Shaughnessy, JD, and Potti, A. "Gene expression profiles of tumor biology provide a novel approach to prognosis and may guide the selection of therapeutic targets in multiple myeloma." Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology 27, no. 25 (September 2009): 4197-4203. Full Text
  - Rizzieri, DA, Dev, P, Long, GD, Gasparetto, C, Sullivan, KM, Horwitz, M, Chute, J, and Chao, NJ. "Response and toxicity of donor lymphocyte infusions following T-cell depleted non-myeloablative allogeneic hematopoietic SCT from 3-6/6 HLA matched donors." Bone Marrow Transplantation 43, no. 4 (February 2009): 327-333. Full Text
  - Horwitz, ME, Morris, A, Gasparetto, C, Sullivan, K, Long, G, Chute, J, Rizzieri, D, McPherson, J, and Chao, N. "Myeloablative intravenous busulfan/fludarabine conditioning does not facilitate reliable engraftment of dual umbilical cord blood grafts in adult recipients." Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation 14, no. 5 (May 2008): 591-594. Full Text
  - Byrne, BJ, Horwitz, M, Long, GD, Gasparetto, C, Sullivan, KM, Chute, J, Chao, NJ, and Rizzieri, DA. "Outcomes of a second non-myeloablative allogeneic stem cell transplantation following graft rejection." Bone Marrow Transplant 41, no. 1 (January 2008): 39-43. Full Text Link to Item
  - Horwitz, ME, Spasojevic, I, Morris, A, Telen, M, Essell, J, Gasparetto, C, Sullivan, K, Long, G, Chute, J, Chao, N, and Rizzieri, D. "Fludarabine-based nonmyeloablative stem cell transplantation for sickle cell disease with and without renal failure: clinical outcome and pharmacokinetics." Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation 13, no. 12 (December 2007): 1422-1426. Full Text
  - Rizzieri, DA, Koh, LP, Long, GD, Gasparetto, C, Sullivan, KM, Horwitz, M, Chute, J, Smith, C, Gong, JZ, Lagoo, A, Niedzwiecki, D, Dowell, JM, Waters-Pick, B, Liu, C, Marshall, D, Vredenburgh, JJ, Gockerman, J, Decastro, C, Moore, J, and Chao, NJ. "Partially matched, nonmyeloablative allogeneic transplantation: clinical outcomes and immune reconstitution." Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology 25, no. 6 (February 2007): 690-697. Full Text
  - Lagoo, AS, Gong, JZ, Stenzel, TT, Goodman, BK, Buckley, PJ, Chao, NJ, Gasparetto, C, Long, GD, and Rizzieri, DA. "Morphologic examination of sequential bone marrow biopsies after nonmyeloablative stem cell transplantation complements molecular studies of donor engraftment." Arch Pathol Lab Med 130, no. 10 (October 2006): 1479-1488. Full Text Link to Item
  - Nieto, Y, Vredenburgh, JJ, Shpall, EJ, Bearman, SI, McSweeney, PA, Chao, N, Rizzieri, D, Gasparetto, C, Matthes, S, Barón, AE, and Jones, RB. "Phase II feasibility and pharmacokinetic study of concurrent administration of trastuzumab and high-dose chemotherapy in advanced HER2+ breast cancer." Clin Cancer Res 10, no. 21 (November 1, 2004): 7136-7143. Full Text Link to Item
  - Chao, NJ, Koh, L-P, Long, GD, Gasparetto, C, Horwitz, M, Morris, A, Lassiter, M, Sullivan, KM, and Rizzieri, DA. "Adult recipients of umbilical cord blood transplants after nonmyeloablative preparative regimens." Biol Blood Marrow Transplant 10, no. 8 (August 2004): 569-575. Full Text Link to Item
  - Rizzieri, DA, Akabani, G, Zalutsky, MR, Coleman, RE, Metzler, SD, Bowsher, JE, Toaso, B, Anderson, E, Lagoo, A, Clayton, S, Pegram, CN, Moore, JO, Gockerman, JP, DeCastro, C, Gasparetto, C, Chao, NJ, and Bigner, DD. "Phase 1 trial study of 131I-labeled chimeric 81C6 monoclonal antibody for the treatment of patients with non-Hodgkin lymphoma." Blood 104, no. 3 (August 2004): 642-648. Full Text
  - Rizzieri, DA, Sand, GJ, McGaughey, D, Moore, JO, DeCastro, C, Chao, NJ, Vredenburgh, JJ, Gasparetto, C, Long, GD, Anderson, E, Foster, T, Toaso, B, Adams, D, Niedzwiecki, D, and Gockerman, JP. "Low-dose weekly paclitaxel for recurrent or refractory aggressive non-Hodgkin lymphoma." Cancer 100, no. 11 (June 1, 2004): 2408-2414. Full Text Link to Item
  - Snyder, MJ, Stenzel, TT, Buckley, PJ, Lagoo, AS, Rizzieri, DA, Gasparetto, C, Vredenburgh, JJ, Chao, NJ, and Gong, JZ. "Posttransplant lymphoproliferative disorder following nonmyeloablative allogeneic stem cell transplantation." Am J Surg Pathol 28, no. 6 (June 2004): 794-800. Link to Item
  - Gasparetto, C. "Stem cell transplantation for multiple myeloma." Cancer Control 11, no. 2 (March 2004): 119-129. (Review) Full Text Link to Item
  - Long, GD, Laughlin, M, Madan, B, Kurtzberg, J, Gasparetto, C, Morris, A, Rizzieri, D, Smith, C, Vredenburgh, J, Halperin, EC, Broadwater, G, Niedzwiecki, D, and Chao, NJ. "Unrelated umbilical cord blood transplantation in adult patients." Biol Blood Marrow Transplant 9, no. 12 (December 2003): 772-780. Full Text Link to Item
  - Rizzieri, DA, Talbot, JT, Long, GD, Vredenburgh, JJ, Gasparetto, C, Smith, CS, Colvin, MO, Adams, D, Morris, A, Dodge, R, Loftis, J, Waters-Pick, B, Reese, M, Carawan, H, Koh, LP, and Chao, NJ. "4-hydroperoxycyclophosphamide--purged peripheral blood stem cells for autologous transplantation in patients with acute myeloid leukemia." Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation 9, no. 3 (March 2003): 183-188. Full Text
  - Rizzieri, DA, Ibom, VK, Moore, JO, DeCastro, CM, Rosner, GL, Adams, DJ, Foster, T, Payne, N, Thompson, M, Vredenburgh, JJ, Gasparetto, C, Long, GD, Chao, NJ, and Gockerman, JP. "Phase I evaluation of prolonged-infusion gemcitabine with fludarabine for relapsed or refractory acute myelogenous leukemia." Clin Cancer Res 9, no. 2 (February 2003): 663-668. Link to Item
  - McCune, SL, Gockerman, JP, Moore, JO, Decastro, CM, Bass, AJ, Chao, NJ, Long, GD, Vredenburgh, JJ, Gasparetto, C, Adams, D, Payne, N, and Rizzieri, DA. "Alemtuzumab in relapsed or refractory chronic lymphocytic leukemia and prolymphocytic leukemia." Leuk Lymphoma 43, no. 5 (May 2002): 1007-1011. Full Text Link to Item
  - Gasparetto, C, Gasparetto, M, Morse, M, Rooney, B, Vredenburgh, JJ, Long, GD, Rizzieri, DA, Loftis, J, Chao, NJ, and Smith, C. "Mobilization of dendritic cells from patients with breast cancer into peripheral blood stem cell leukapheresis samples using Flt-3-Ligand and G-CSF or GM-CSF." Cytokine 18, no. 1 (April 2002): 8-19. Full Text
  - Chao, NJ, Liu, CX, Rooney, B, Chen, BJ, Long, GD, Vredenburgh, JJ, Morris, A, Gasparetto, C, and Rizzieri, DA. "Nonmyeloablative regimen preserves "niches" allowing for peripheral expansion of donor T-cells." Biol Blood Marrow Transplant 8, no. 5 (2002): 249-256. Link to Item
  - Rizzieri, DA, Long, GD, Vredenburgh, JJ, Gasparetto, C, Morris, A, Stenzel, TT, Davis, P, and Chao, NJ. "Successful allogeneic engraftment of mismatched unrelated cord blood following a nonmyeloablative preparative regimen." Blood 98, no. 12 (December 2001): 3486-3488. Full Text
  - Gasparetto, C, Smith, C, Gillio, A, Stoppa, AM, Moore, MA, and O'Reilly, RJ. "Enrichment of peripheral blood stem cells in a primate model following administration of a single dose of rh-IL-1 beta." Bone Marrow Transplant 14, no. 5 (November 1994): 717-723. Link to Item
  - Dennig, D, Lacerda, J, Yan, Y, Gasparetto, C, and O'Reilly, RJ. "ICAM-1 (CD54) expression on B lymphocytes is associated with their costimulatory function and can be increased by coactivation with IL-1 and IL-7." Cell Immunol 156, no. 2 (July 1994): 414-423. Full Text Link to Item
  - Gasparetto, C, Smith, C, Firpo, M, Dennig, D, Small, T, Gillio, AP, Lichtenberg, R, O'Reilly, RJ, and Moore, MA. "Dyshematopoiesis in combined immune deficiency with congenital neutropenia." Am J Hematol 45, no. 1 (January 1994): 63-72. Link to Item
  - Muench, MO, Gasparetto, C, and Moore, MA. "The in vitro growth of murine high proliferative potential-colony forming cells is not enhanced by growth in a low oxygen atmosphere." Cytokine 4, no. 6 (November 1992): 488-494. Link to Item
  - Crown, J, Jakubowski, A, Kemeny, N, Gordon, M, Gasparetto, C, Wong, G, Sheridan, C, Toner, G, Meisenberg, B, and Botet, J. "A phase I trial of recombinant human interleukin-1 beta alone and in combination with myelosuppressive doses of 5-fluorouracil in patients with gastrointestinal cancer." Blood 78, no. 6 (September 1991): 1420-1427.
  - Smith, C, Gasparetto, C, Collins, N, Gillio, A, Muench, MO, O'Reilly, RJ, and Moore, MA. "Purification and partial characterization of a human hematopoietic precursor population." Blood 77, no. 10 (May 1991): 2122-2128.
  - Lemoli, RM, Gasparetto, C, Scheinberg, DA, Moore, MA, Clarkson, BD, and Gulati, SC. "Autologous bone marrow transplantation in acute myelogenous leukemia: in vitro treatment with myeloid-specific monoclonal antibodies and drugs in combination." Blood 77, no. 8 (April 15, 1991): 1829-1836. Link to Item
  - Gillio, AP, Gasparetto, C, Laver, J, Abboud, M, Bonilla, MA, Garnick, MB, and O'Reilly, RJ. "Effects of interleukin-3 on hematopoietic recovery after 5-fluorouracil or cyclophosphamide treatment of cynomolgus primates." J Clin Invest 85, no. 5 (May 1990): 1560-1565. Full Text Link to Item
  - Laver, J, Duncan, E, Abboud, M, Gasparetto, C, Sahdev, I, Warren, D, Bussel, J, Auld, P, O'Reilly, RJ, and Moore, MA. "High levels of granulocyte and granulocyte-macrophage colony-stimulating factors in cord blood of normal full-term neonates." J Pediatr 116, no. 4 (April 1990): 627-632. Link to Item
  - O'Reilly, RJ, Gillio, A, and Gasparetto, C. "Effects of hematopoietic growth factors following myeloablation in a primate model." Int J Cell Cloning 8 Suppl 1 (January 1990): 262-267. Full Text Link to Item
  - Gasparetto, C, Laver, J, Abboud, M, Gillio, A, Smith, C, O'Reilly, RJ, and Moore, MA. "Effects of interleukin-1 on hematopoietic progenitors: evidence of stimulatory and inhibitory activities in a primate model." Blood 74, no. 2 (August 1, 1989): 547-550. Link to Item
  - Laver, J, Abboud, M, Gasparetto, C, Gillio, A, Smith, C, O'Reilly, RJ, and Moore, MA. "Effects of IL-1 on hematopoietic progenitors after myelosuppressive chemoradiotherapy." Biotherapy 1, no. 4 (1989): 293-300. Link to Item
- Conference Papers
  - Anand, S, Thomas, S, Corbet, K, Gasparetto, C, Long, GD, Lopez, R, Morris, AK, Rizzieri, DA, Sullivan, KM, Sung, AD, Sarantopoulos, S, Chao, NJ, and Horwitz, ME. "Adult Umbilical Cord Blood Transplantation Using Myeloablative Thiotepa, Total Body Irradiation, and Fludarabine Conditioning." November 2017. Full Text
  - Richardson, PG, Schlossman, RL, Alsina, M, Weber, DM, Coutre, SE, Gasparetto, C, Mukhopadhyay, S, Ondovik, MS, Khan, M, Paley, CS, and Lonial, S. "PANORAMA 2: panobinostat in combination with bortezomib and dexamethasone in patients with relapsed and bortezomib-refractory myeloma." October 2013. Full Text

Some information on this profile has been compiled automatically from Duke databases and external sources. (Our About page explains how this works.) If you see a problem with the information, please write to Scholars@Duke and let us know. We will reply promptly.

Education, Training, & Certifications

Duke Appointment History

Selected Grants

Selected Publications

Academic Articles

Conference Papers